SPRY vs. KRYS, SWTX, BHVN, RXRX, PTCT, OGN, RARE, ALVO, RNA, and ADMA
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), Biohaven (BHVN), Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Avidity Biosciences (RNA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
ARS Pharmaceuticals vs.
ARS Pharmaceuticals (NASDAQ:SPRY) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.
ARS Pharmaceuticals has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Krystal Biotech has a net margin of 30.69% compared to ARS Pharmaceuticals' net margin of 0.00%. Krystal Biotech's return on equity of 11.41% beat ARS Pharmaceuticals' return on equity.
Krystal Biotech received 271 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 84.62% of users gave ARS Pharmaceuticals an outperform vote while only 67.51% of users gave Krystal Biotech an outperform vote.
Krystal Biotech has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
In the previous week, Krystal Biotech had 28 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 32 mentions for Krystal Biotech and 4 mentions for ARS Pharmaceuticals. Krystal Biotech's average media sentiment score of 0.75 beat ARS Pharmaceuticals' score of 0.56 indicating that Krystal Biotech is being referred to more favorably in the news media.
ARS Pharmaceuticals presently has a consensus target price of $28.80, suggesting a potential upside of 156.23%. Krystal Biotech has a consensus target price of $210.00, suggesting a potential upside of 11.79%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than Krystal Biotech.
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Krystal Biotech beats ARS Pharmaceuticals on 12 of the 19 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SPRY) was last updated on 2/21/2025 by MarketBeat.com Staff
Free SPRY Stock Alerts